Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …

With the discovery of PROteolysis TArgeting Chimeras (PROTACs) twenty years ago,
targeted protein degradation (TPD) has changed the landscape of drug development …

Colorectal cancer (CRC), a leading cause of cancer-related mortalities globally, results from
the accumulation of multiple genetic and epigenetic alterations in the normal colonic and …

Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten
rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS …

Introduction Undruggable targets refer to clinically meaningful therapeutic targets that are
'difficult to drug'or 'yet to be drugged'via traditional approaches. Featuring characteristics of …

Activating mutants of RAS are commonly found in human cancers, but to date selective
targeting of RAS in the clinic has been limited to KRAS (G12C) through covalent inhibitors …

Targeted protein degradation and stabilization are promising therapeutic modalities
because of their potency, versatility and their potential to expand the druggable target …

In the 20 years since the first report of a proteolysis targeting chimeric (PROTAC) molecule,
targeted protein degradation (TPD) technologies have attempted to revolutionize the fields …